Combined therapy with daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b: a case report.
- Author:
Sai-Nan PI
1
;
You-Peng CHEN
Author Information
1. Department of Infectious Diseases, First Affiliated Hospital of Jinan University, Guangzhou 510630, China. E-mail: 874345904@qq.com.
- Publication Type:Case Reports
- MeSH:
Adult;
Antiviral Agents;
therapeutic use;
Female;
Genotype;
Hepacivirus;
genetics;
Hepatitis C, Chronic;
drug therapy;
Humans;
Imidazoles;
therapeutic use;
Isoquinolines;
therapeutic use;
Sulfonamides;
therapeutic use
- From:
Journal of Southern Medical University
2016;36(8):1163-1164
- CountryChina
- Language:Chinese
-
Abstract:
The combination therapy with daclatasvir and asunaprevir can achieve a high sustained viral response rate against hepatitis C virus (HCV) genotype 1, but so far this regimen has not been reported in the treatment of Chinese patients with chronic hepatitis C (CHC) genotype 1b. Here we report a case of CHC genotype 1b in a 44-year-old female chinese patient who was treated with this regimen for 24 weeks. The patient showed sustained viral response after the treatment and was clinically cured. During the treatment, the patient experienced a transient elevation of serum total bilirubin accompanied by lowered hemoglobin fluctuating between 100 and 110 g/L.
